233 related articles for article (PubMed ID: 27634757)
21. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
[TBL] [Abstract][Full Text] [Related]
22. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
23. Advances in the understanding of myeloma bone disease and tumour growth.
Yaccoby S
Br J Haematol; 2010 May; 149(3):311-21. PubMed ID: 20230410
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
25. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.
Spaan I; Raymakers RA; van de Stolpe A; Peperzak V
J Hematol Oncol; 2018 May; 11(1):67. PubMed ID: 29776381
[TBL] [Abstract][Full Text] [Related]
26. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
[TBL] [Abstract][Full Text] [Related]
27. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
28. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
29. [SDF-1/CXCR4 and multiple myeloma osteolytic bone lesions--review].
Bao L; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):442-6. PubMed ID: 18426683
[TBL] [Abstract][Full Text] [Related]
30. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
31. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
32. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
Asosingh K
Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
[TBL] [Abstract][Full Text] [Related]
33. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
Kassen D; Lath D; Lach A; Evans H; Chantry A; Rabin N; Croucher P; Yong KL
Br J Haematol; 2016 Jan; 172(1):64-79. PubMed ID: 26767468
[TBL] [Abstract][Full Text] [Related]
34. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.
Vallet S; Mukherjee S; Vaghela N; Hideshima T; Fulciniti M; Pozzi S; Santo L; Cirstea D; Patel K; Sohani AR; Guimaraes A; Xie W; Chauhan D; Schoonmaker JA; Attar E; Churchill M; Weller E; Munshi N; Seehra JS; Weissleder R; Anderson KC; Scadden DT; Raje N
Proc Natl Acad Sci U S A; 2010 Mar; 107(11):5124-9. PubMed ID: 20194748
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
36. Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance.
Helfrich MH; Livingston E; Franklin IM; Soutar RL
Blood Rev; 1997 Mar; 11(1):28-38. PubMed ID: 9218104
[TBL] [Abstract][Full Text] [Related]
37. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
[TBL] [Abstract][Full Text] [Related]
39. Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma.
Vatolin S; Phillips JG; Jha BK; Govindgari S; Hu J; Grabowski D; Parker Y; Lindner DJ; Zhong F; Distelhorst CW; Smith MR; Cotta C; Xu Y; Chilakala S; Kuang RR; Tall S; Reu FJ
Cancer Res; 2016 Jun; 76(11):3340-50. PubMed ID: 27197150
[TBL] [Abstract][Full Text] [Related]
40. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
